格隆汇1月22日丨康龙化成(03759.HK)宣布，已达成所有条件并于2026年1月22日完成配售。配售代理已 根据配售协议的条款及条件，按每股配售股份配售价22.82港元，成功向不少于六名独立承配人配售合 共5844.08万股配售股份。 配售的募集资金净额为13.19亿港元，将按以下方式投入使用：(a)约70%将用于公司的项目建设，以加 强本公司实验室服务设施、药物工艺开发及生产设施的能力及产能；(b)约10%将用于偿还银行贷款及其 他借款，以优化公司的资本结构；及(c)约20%将用于补充营运资金及作其他一般公司用途。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03759 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴該等 內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的任何其他司法 權區內刊發或派發。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 本公告並非，亦不構成於美國（定義見1933年《美國證券法》（「《證券法》」）S規例）出售證券的 要約或邀請及其任何部分。本公告或其任何內容或其副本亦不得攜進美國境內或於美國境內或 在刊發或派發本公告屬違法的任何其他司法權區內直接或間接派發。除非本公告所指證券根據 《證券法》辦理登記或獲豁免遵守《證券法》的登記規定，否則有關證券未曾亦不會根據《證券 法》登記，且不得在美國境內提呈發售、出售或以其他方式轉讓。本公司並無計劃在美國登記 本公告所述任何證券或在美國公開發售任何證券。 配售的募集資金淨額為1,318.7百萬港元，將按以下方式投入使用： Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 ...

Group 1 - The core viewpoint of the article highlights that 康龙化成 (Crown Bioscience) is experiencing a decline in stock price, dropping over 3% to HKD 22.12, with a trading volume of HKD 113 million [2] - On January 15, 康龙化成 announced a plan to place nearly 58.44 million new H-shares at a price of HKD 22.82 per share, representing an approximate 8.5% discount to the closing price on January 14, aiming to raise a net amount of about HKD 1.319 billion [2] - Approximately 70% of the funds raised will be allocated to project construction to enhance laboratory service facilities, drug process development, and production capacity [2] Group 2 - 康龙化成 recently released an earnings forecast, projecting a net profit attributable to shareholders for 2025 to be between HKD 1.614 billion and HKD 1.686 billion, reflecting a decrease of 6% to 10% compared to the previous year [2] - During the reporting period, the company's operating revenue is expected to grow by 13% to 16%, while the net profit after excluding non-recurring gains and losses is anticipated to increase by 36% to 41% year-on-year [2]

每经AI快讯，康龙化成(03759.HK)再跌超3%，截至发稿跌3.41%，报22.12港元，成交额1.13亿港元。 ...

Core Viewpoint - Kanglong Chemical (03759) has seen a decline of over 3%, currently trading at HKD 22.12, with a transaction volume of HKD 113 million [1] Group 1: Fundraising and Stock Issuance - On January 15, Kanglong Chemical announced a plan to issue nearly 58.44 million new H-shares at a price of HKD 22.82 per share, representing a discount of approximately 8.5% compared to the closing price on January 14 [1] - The net proceeds from this fundraising are expected to be around HKD 1.319 billion, with approximately 70% allocated for project construction to enhance laboratory service facilities, drug process development, and production capacity [1] Group 2: Earnings Forecast - Kanglong Chemical recently released an earnings forecast, projecting a net profit attributable to shareholders for 2025 to be between HKD 1.614 billion and HKD 1.686 billion, indicating a year-on-year decline of 6% to 10% [1] - During the reporting period, the company's operating revenue is expected to grow by 13% to 16%, while the net profit after excluding non-recurring gains and losses is anticipated to increase by 36% to 41% year-on-year [1]

消息面上，1月15日，康龙化成发布公告，拟配售近5844.08万股新H股，配售价每股22.82港元，较1月 14日收市价折让约8.5%，募资所得款项净额约13.19亿港元，其中约70%将用于公司的项目建设，以加 强实验室服务设施、药物工艺开发及生产设施的能力及产能。 康龙化成（300759）(03759)再跌超3%，截至发稿，跌3.41%，报22.12港元，成交额1.13亿港元。 此外，康龙化成近日公布业绩预告，预计2025年归属于上市公司股东的净利润为16.14亿元-16.86亿元， 比上年同期下降6%-10%。报告期内，公司营业收入同比增长13%-16%，扣除非经常性损益后的净利润 同比增长36%-41%。 ...

Group 1 - The stock of Kanglong Chemical (03759.HK) has dropped over 3%, currently down 3.44% at HKD 23.04 [2] - The trading volume reached HKD 157 million [2]

Core Viewpoint - Kanglong Chemical (03759) has seen a decline of over 3%, currently trading at HKD 23.04 with a transaction volume of HKD 157 million [1] Group 1: Company Announcement - Kanglong Chemical announced a proposed placement of approximately 58.44 million new H-shares, representing about 3.19% of the company's enlarged total issued shares and approximately 16.57% of the total issued H-shares [1] - The placement price is set at HKD 22.82 per share, reflecting a discount of approximately 8.5% compared to the closing price on January 14 [1] Group 2: Use of Proceeds - The company expects total gross proceeds and net proceeds from the placement to be approximately HKD 1.334 billion and HKD 1.319 billion, respectively [1] - Approximately 70% of the proceeds will be used for project construction to enhance laboratory service facilities, drug process development, and production capacity [1] - About 10% of the proceeds will be allocated to repay bank loans and other borrowings to optimize the capital structure, while the remaining 20% will be used to supplement working capital and for other general purposes [1]

Core Viewpoint - 康龙化成 announced a placement of approximately 58.44 million new H-shares, representing about 3.19% of the company's expanded total issued shares and about 16.57% of the total issued H-shares, at a price of HKD 22.82 per share, which is an 8.5% discount compared to the closing price on January 14 [1] Group 1 - The company’s stock fell by 3.44% to HKD 23.04, with a trading volume of HKD 157 million [1] - The expected total amount raised from the placement is approximately HKD 13.34 billion, with a net amount of about HKD 13.19 billion [1] - Approximately 70% of the proceeds will be used for project construction to enhance laboratory service facilities, drug process development, and production capacity [1] Group 2 - About 10% of the proceeds will be allocated to repay bank loans and other borrowings to optimize the capital structure [1] - The remaining 20% will be used to supplement working capital and for other general purposes [1]